Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
1.110
-0.170 (-13.28%)
At close: Nov 16, 2026, 4:00 PM EST
1.140
+0.030 (2.70%)
After-hours: Nov 16, 2026, 7:58 PM EST
Cabaletta Bio Stock Forecast
CABA's stock price has decreased by -51.95% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 10 analysts polled by S&P Global, Cabaletta Bio stock has a consensus rating of "Buy" and an average price target of $11.75. The average 1-year stock price forecast is 958.56% higher than the current stock price, while the lowest is $3.00 (+170.27%) and the highest is $20 (+1,701.80%).
Price Target: $11.75 (+958.56%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Cabaletta Bio stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $10 → $8 | Buy | Maintains | $10 → $8 | +620.72% | Nov 9, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $13 | Buy | Maintains | $13 | +1,071.17% | Nov 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $16 | Buy | Reiterates | $16 | +1,341.44% | Nov 6, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 2, 2026 |
Unknown Analyst Wells Fargo No rating | Wells Fargo | Hold Reiterates $3 | Hold | Reiterates | $3 | +170.27% | Sep 1, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.29
from -2.10
EPS Next Year
-1.13
from -1.29
EPS and Forward PE are based on non-GAAP adjusted numbers.